Temple OrthoBiologics aims to address issues with scar tissue in joints, the news release said. The company’s flagship product is TX-33, which is designed for muscle recovery and repair in athletes. The product aims to prevent scar tissue from forming after an injury or surgery.
The company’s research and development hub is in Belgium and has partnerships in the U.S., Netherlands and Canada.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
